The Women's Health segment focuses on reproductive genetic testing services. This includes the Panorama test, a non-invasive prenatal test (NIPT) that screens for chromosomal abnormalities in a fetus using a blood draw from the mother. Vistara, a single-gene mutation screening test, and Horizon carrier screening are also offered. Research and development activities in this segment are focused on improving the accuracy and expanding the scope of NIPT, developing new tests for single-gene disorders, and enhancing carrier screening panels. Technologies used include cell-free DNA analysis, next-generation sequencing (NGS), and bioinformatics. The segment addresses the needs of pregnant women and couples planning to conceive, providing information about the health of the fetus and the parents' carrier status. Market positioning is strong due to the non-invasive nature and high accuracy of the tests. Future opportunities include expanding into new areas of reproductive health and developing more comprehensive screening panels. Regulatory and clinical aspects involve obtaining FDA approval and conducting clinical trials to validate the tests. Partnerships with laboratories and distribution partners are crucial for market access.

The Oncology segment focuses on developing and commercializing circulating tumor DNA (ctDNA) testing for cancer management. The primary product in this segment is Signatera, a personalized ctDNA test used to monitor for minimal residual disease (MRD) and recurrence in cancer patients. Research and development efforts are focused on improving the sensitivity and specificity of ctDNA detection, expanding the test's applications to different cancer types, and developing new biomarkers for early cancer detection. Technologies used include NGS, advanced bioinformatics, and machine learning algorithms. The segment addresses the needs of cancer patients by providing a tool for early detection of cancer recurrence, guiding treatment decisions, and monitoring treatment response. Market positioning is strong due to the test's ability to detect cancer recurrence earlier than traditional methods. Future opportunities include expanding into early cancer detection and developing companion diagnostics. Regulatory and clinical aspects involve obtaining FDA approval and conducting clinical trials to validate the test's clinical utility. Partnerships with pharmaceutical companies and research institutions are crucial for clinical trial development and market access.

The Organ Health segment focuses on developing and commercializing tests for assessing organ transplant rejection. The primary product is Prospera, a cell-free DNA (cfDNA) test used to assess the risk of rejection in kidney transplant recipients. Research and development activities are focused on improving the accuracy and expanding the applications of cfDNA testing in other solid organ transplants. Technologies used include cell-free DNA analysis and NGS. The segment addresses the needs of transplant recipients by providing a non-invasive method to monitor for organ rejection, enabling earlier intervention and improved patient outcomes. Market positioning is strong due to the test's ability to detect rejection earlier than traditional methods. Future opportunities include expanding into other solid organ transplants and developing new biomarkers for transplant monitoring. Regulatory and clinical aspects involve obtaining FDA approval and conducting clinical trials to validate the test's clinical utility. Partnerships with transplant centers and pharmaceutical companies are crucial for market access and clinical trial development.